[HTML][HTML] The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Q Tang, Y Chen, X Li, S Long, Y Shi, Y Yu… - Frontiers in …, 2022 - frontiersin.org
Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …
Mismatch repair deficiency and clinical implications in prostate cancer
LS Graham, MT Schweizer - The Prostate, 2022 - Wiley Online Library
Despite recent therapeutic advances, castration‐resistant prostate cancer (CRPC) remains a
lethal disease and novel therapies are needed. Precision oncology provides an avenue for …
lethal disease and novel therapies are needed. Precision oncology provides an avenue for …
The role of programmed death receptor (PD‐) 1/PD‐ligand (L) 1 in periodontitis and cancer
S Groeger, J Meyle - Periodontology 2000, 2024 - Wiley Online Library
Abstract The programmed‐death‐ligand‐1 (PD‐L1) is an immune‐modulating molecule that
is constitutively expressed on various immune cells, different epithelial cells and a multitude …
is constitutively expressed on various immune cells, different epithelial cells and a multitude …
Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment
Y Wang, M Yang, M Tao, P Liu, C Kong, H Li… - International …, 2021 - Elsevier
Objective Immunotherapies targeting immune checkpoints have achieved encouraging
survival benefits in patients with various solid cancers. Corticosteroids are frequently …
survival benefits in patients with various solid cancers. Corticosteroids are frequently …
[HTML][HTML] Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non …
K Hosoya, D Fujimoto, T Morimoto, T Kumagai… - BMC cancer, 2021 - Springer
Background Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer
chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are …
chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are …
Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles
J Deng, H Ke - Oncoimmunology, 2023 - Taylor & Francis
Extracellular vesicles (EVs) are promising tools for drug delivery across different biological
barriers. Here, we evaluated the potential of EVs-mediated delivery of CD38 siRNA on the …
barriers. Here, we evaluated the potential of EVs-mediated delivery of CD38 siRNA on the …
[HTML][HTML] IL-3 signalling in the tumour microenvironment shapes the immune response via tumour endothelial cell-derived extracellular vesicles
T Lopatina, M Koni, C Grange, M Cedrino… - Pharmacological …, 2022 - Elsevier
Antibody-based anti-cancer therapy is considered a successful approach to impair tumour
progression. This study aimed to investigate the clinical impact of targeting the IL-3 …
progression. This study aimed to investigate the clinical impact of targeting the IL-3 …
Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death‐ligand 1 inhibitors in …
LC Villaruz, GR Blumenschein Jr, GA Otterson… - Cancer, 2023 - Wiley Online Library
The availability of agents targeting the programmed cell death protein 1 (PD‐1)/programmed
death‐ligand 1 (PD‐L1) immune checkpoint has transformed treatment of advanced and/or …
death‐ligand 1 (PD‐L1) immune checkpoint has transformed treatment of advanced and/or …
[HTML][HTML] A radiomics nomogram prediction for survival of patients with “driver gene-negative” lung adenocarcinomas (LUAD)
Background To study the role of computed tomography (CT)-derived radiomics features and
clinical characteristics on the prognosis of “driver gene-negative” lung adenocarcinoma …
clinical characteristics on the prognosis of “driver gene-negative” lung adenocarcinoma …
[HTML][HTML] Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical …
DR Castillo, WJ Jeon, D Park, B Pham, C Yang… - International Journal of …, 2023 - mdpi.com
In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer
(NSCLC), have advanced significantly, offering tailored treatment options for patients …
(NSCLC), have advanced significantly, offering tailored treatment options for patients …